Literature DB >> 15124019

Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production.

Meihui Pan1, Arthur I Cederbaum, Yuan-Li Zhang, Henry N Ginsberg, Kevin Jon Williams, Edward A Fisher.   

Abstract

How omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) lower plasma lipid levels is incompletely understood. We previously showed that marine omega-3 PUFAs (docosahexaenoic acid [DHA] and eicosapentaenoic acid) stimulate a novel pathway, post-ER presecretory proteolysis (PERPP), that degrades apolipoprotein B100 (ApoB100), thereby reducing lipoprotein secretion from liver cells. To identify signals stimulating PERPP, we examined known actions of omega-3 PUFA. In rat hepatoma or primary rodent hepatocytes incubated with omega-3 PUFA, cotreatment with the iron chelator desferrioxamine, an inhibitor of iron-dependent lipid peroxidation, or vitamin E, a lipid antioxidant, suppressed increases in thiobarbituric acid-reactive substances (TBARSs; a measure of lipid peroxidation products) and restored ApoB100 recovery and VLDL secretion. Moreover, omega-6 and nonmarine omega-3 PUFA, also prone to peroxidation, increased ApoB100 degradation via intracellular induction of TBARSs. Even without added fatty acids, degradation of ApoB100 in primary hepatocytes was blocked by desferrioxamine or antioxidant cotreatment. To extend these results in vivo, mice were infused with DHA, which increased hepatic TBARSs and reduced VLDL-ApoB100 secretion. These results establish a novel link between lipid peroxidation and oxidant stress with ApoB100 degradation via PERPP, and may be relevant to the hypolipidemic actions of dietary PUFAs, the basal regulation of ApoB100 secretion, and hyperlipidemias arising from ApoB100 overproduction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15124019      PMCID: PMC398425          DOI: 10.1172/JCI19197

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  84 in total

1.  Fish oil feeding alters liver gene expressions to defend against PPARalpha activation and ROS production.

Authors:  Mayumi Takahashi; Nobuyo Tsuboyama-Kasaoka; Teruyo Nakatani; Masami Ishii; Shuichi Tsutsumi; Hiroyuki Aburatani; Osamu Ezaki
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-02       Impact factor: 4.052

2.  Positional cloning of the combined hyperlipidemia gene Hyplip1.

Authors:  Jackie S Bodnar; Aurobindo Chatterjee; Lawrence W Castellani; David A Ross; Jeffrey Ohmen; James Cavalcoli; Chenyan Wu; Katherine M Dains; Joe Catanese; Michael Chu; Sonal S Sheth; Kanti Charugundla; Peter Demant; David B West; Pieter de Jong; Aldons J Lusis
Journal:  Nat Genet       Date:  2001-12-20       Impact factor: 38.330

3.  Hydrogen peroxide generated during cellular insulin stimulation is integral to activation of the distal insulin signaling cascade in 3T3-L1 adipocytes.

Authors:  K Mahadev; X Wu; A Zilbering; L Zhu; J T Lawrence; B J Goldstein
Journal:  J Biol Chem       Date:  2001-10-11       Impact factor: 5.157

4.  Radioactive labeling of antibody: a simple and efficient method.

Authors:  D J Hnatowich; W W Layne; R L Childs; D Lanteigne; M A Davis; T W Griffin; P W Doherty
Journal:  Science       Date:  1983-05-06       Impact factor: 47.728

5.  Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100.

Authors:  L G Fong; S Parthasarathy; J L Witztum; D Steinberg
Journal:  J Lipid Res       Date:  1987-12       Impact factor: 5.922

6.  Insulin effects on apolipoprotein B lipoprotein synthesis and secretion by primary cultures of rat hepatocytes.

Authors:  C E Sparks; J D Sparks; M Bolognino; A Salhanick; P S Strumph; J M Amatruda
Journal:  Metabolism       Date:  1986-12       Impact factor: 8.694

7.  Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site.

Authors:  E Graf; J R Mahoney; R G Bryant; J W Eaton
Journal:  J Biol Chem       Date:  1984-03-25       Impact factor: 5.157

8.  Intrahepatic assembly of very low density lipoproteins. Rate of transport out of the endoplasmic reticulum determines rate of secretion.

Authors:  R A Borchardt; R A Davis
Journal:  J Biol Chem       Date:  1987-12-05       Impact factor: 5.157

9.  Modes of action of lipid-lowering diets in man: studies of apolipoprotein B kinetics in relation to fat consumption and dietary fatty acid composition.

Authors:  C Cortese; Y Levy; E D Janus; P R Turner; S N Rao; N E Miller; B Lewis
Journal:  Eur J Clin Invest       Date:  1983-02       Impact factor: 4.686

10.  Calcium-antagonists inhibit secretion of very-low-density lipoprotein from cultured rat hepatocytes.

Authors:  J O Nossen; A C Rustan; C A Drevon
Journal:  Biochem J       Date:  1987-10-15       Impact factor: 3.857

View more
  72 in total

1.  Hepatic very-low-density lipoprotein and apolipoprotein B production are increased following in vivo induction of betaine-homocysteine S-methyltransferase.

Authors:  Janet D Sparks; Heidi L Collins; Doru V Chirieac; Joanne Cianci; Jenny Jokinen; Mark P Sowden; Chad A Galloway; Charles E Sparks
Journal:  Biochem J       Date:  2006-04-15       Impact factor: 3.857

Review 2.  Hepatic regulation of apolipoprotein B.

Authors:  Rita Kohen Avramoglu; Khosrow Adeli
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

3.  Role of superoxide radical anion in the mechanism of apoB100 degradation induced by DHA in hepatic cells.

Authors:  Ursula Andreo; Josh Elkind; Courtney Blachford; Arthur I Cederbaum; Edward A Fisher
Journal:  FASEB J       Date:  2011-07-14       Impact factor: 5.191

Review 4.  Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.

Authors:  David E Cohen; Edward A Fisher
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

Review 5.  Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?

Authors:  Lynley M Doonan; Edward A Fisher; Jeffrey L Brodsky
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-04-06       Impact factor: 4.698

Review 6.  Omega-6 fatty acids and coronary artery disease: the pros and cons.

Authors:  Gal Dubnov; Elliot M Berry
Journal:  Curr Atheroscler Rep       Date:  2004-11       Impact factor: 5.113

7.  GCN2 is required to increase fibroblast growth factor 21 and maintain hepatic triglyceride homeostasis during asparaginase treatment.

Authors:  Gabriel J Wilson; Brittany A Lennox; Pengxiang She; Emily T Mirek; Rana J T Al Baghdadi; Michael E Fusakio; Joseph L Dixon; Gregory C Henderson; Ronald C Wek; Tracy G Anthony
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-12-09       Impact factor: 4.310

Review 8.  Molecular mediators of hepatic steatosis and liver injury.

Authors:  Jeffrey D Browning; Jay D Horton
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 9.  Omega-3 fatty acid supplementation and cardiovascular disease.

Authors:  Donald B Jump; Christopher M Depner; Sasmita Tripathy
Journal:  J Lipid Res       Date:  2012-08-17       Impact factor: 5.922

10.  Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis.

Authors:  J Mark Brown; Soonkyu Chung; Janet K Sawyer; Chiara Degirolamo; Heather M Alger; Tam M Nguyen; Xuewei Zhu; My-Ngan Duong; Amanda L Brown; Caleb Lord; Ramesh Shah; Matthew A Davis; Kathryn Kelley; Martha D Wilson; Jennifer Madenspacher; Michael B Fessler; John S Parks; Lawrence L Rudel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-15       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.